Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Effect of trastuzumab interchain disulfide bond cleavage on Fcγ receptor binding and antibody-dependent tumour cell phagocytosis.

Suzuki M, Yamanoi A, Machino Y, Ootsubo M, Izawa K, Kohroki J, Masuho Y.

J Biochem. 2016 Jan;159(1):67-76. doi: 10.1093/jb/mvv074. Epub 2015 Aug 8.

2.

Subtypes of metabolic syndrome and of other risk factors in Japanese women with erosive esophagitis.

Sogabe M, Okahisa T, Yamanoi A, Takayama T.

Medicine (Baltimore). 2014 Dec;93(28):e276. doi: 10.1097/MD.0000000000000276.

3.

Cleavage of the interchain disulfide bonds in rituximab increases its affinity for FcγRIIIA.

Suzuki M, Yamanoi A, Machino Y, Kobayashi E, Fukuchi K, Tsukimoto M, Kojima S, Kohroki J, Akimoto K, Masuho Y.

Biochem Biophys Res Commun. 2013 Jul 5;436(3):519-24. doi: 10.1016/j.bbrc.2013.05.137. Epub 2013 Jun 10.

PMID:
23764395
4.

Visceral fat predominance is associated with non-alcoholic fatty liver disease in Japanese women with metabolic syndrome.

Sogabe M, Okahisa T, Tsujigami K, Fukuno H, Hibino S, Yamanoi A.

Hepatol Res. 2014 May;44(5):515-22. doi: 10.1111/hepr.12146. Epub 2013 May 22.

PMID:
23617326
5.

Visceral fat predominance is associated with erosive esophagitis in Japanese men with metabolic syndrome.

Sogabe M, Okahisa T, Kimura Y, Hibino S, Yamanoi A.

Eur J Gastroenterol Hepatol. 2012 Aug;24(8):910-6. doi: 10.1097/MEG.0b013e328354a354.

PMID:
22617364
6.

Usefulness of differentiating metabolic syndrome into visceral fat type and subcutaneous fat type using ultrasonography in Japanese males.

Sogabe M, Okahisa T, Hibino S, Yamanoi A.

J Gastroenterol. 2012 Mar;47(3):293-9. doi: 10.1007/s00535-011-0489-4. Epub 2011 Nov 9.

PMID:
22065161
7.

Reconstruction of the gastrointestinal tract by hemi-double stapling method for the esophagus and jejunum using EEA OrVil in laparoscopic total gastrectomy and proximal gastrectomy.

Hirahara N, Tanaka T, Yano S, Yamanoi A, Minari Y, Kawabata Y, Ueda S, Hira E, Yamamoto T, Nishi T, Hyakudomi R, Inao T.

Surg Laparosc Endosc Percutan Tech. 2011 Feb;21(1):e11-5. doi: 10.1097/SLE.0b013e31820747f2.

PMID:
21304364
8.

TNF receptor II fusion protein with tandemly repeated Fc domains.

Nagashima H, Kaneko K, Yamanoi A, Motoi S, Konakahara S, Kohroki J, Masuho Y.

J Biochem. 2011 Mar;149(3):337-46. doi: 10.1093/jb/mvq149. Epub 2011 Jan 28.

PMID:
21278157
9.

Hemoperfusion with a high-mobility group box 1 adsorption column can prevent the occurrence of hepatic ischemia-reperfusion injury in rats.

Yamamoto T, Ono T, Ito T, Yamanoi A, Maruyama I, Tanaka T.

Crit Care Med. 2010 Mar;38(3):879-85. doi: 10.1097/CCM.0b013e3181c58951.

PMID:
20029346
10.

A resected case of liver metastasis from colon cancer that occurred 13 years after a colectomy.

Yamaguchi M, Yamanoi A, Igarashi M, Obmori H, Yoshimura H, Tanaka T, Nagasue N.

Hepatogastroenterology. 2008 Nov-Dec;55(88):2221-3.

PMID:
19260509
11.

Role of peroxisome proliferator-activated receptor-gamma (PPARgamma) during liver regeneration in rats.

Yamamoto Y, Ono T, Dhar DK, Yamanoi A, Tachibana M, Tanaka T, Nagasue N.

J Gastroenterol Hepatol. 2008 Jun;23(6):930-7. doi: 10.1111/j.1440-1746.2008.05370.x.

PMID:
18565023
12.

Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma.

Hyakudomi M, Matsubara T, Hyakudomi R, Yamamoto T, Kinugasa S, Yamanoi A, Maruyama R, Tanaka T.

Ann Surg Oncol. 2008 Jun;15(6):1775-82. doi: 10.1245/s10434-008-9876-3. Epub 2008 Mar 25.

PMID:
18363071
13.

Experimental investigation of the role of endothelin-1 in idiopathic portal hypertension.

Yamaguchi E, Yamanoi A, Ono T, Nagasue N.

J Gastroenterol Hepatol. 2007 Jul;22(7):1134-40.

PMID:
17608860
14.

Our experiences in surgical treatment for hilar cholangiocarcinoma.

Maeno H, Ono T, Yamanoi A, Nagasue N.

Hepatogastroenterology. 2007 Apr-May;54(75):669-73.

PMID:
17591038
15.

FR-167653, a selective p38 MAPK inhibitor, exerts salutary effect on liver cirrhosis through downregulation of Runx2.

Hattori S, Dhar DK, Hara N, Tonomoto Y, Onoda T, Ono T, Yamanoi A, Tachibana M, Tsuchiya M, Nagasue N.

Lab Invest. 2007 Jun;87(6):591-601. Epub 2007 Mar 5.

16.

Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma.

Matsubara T, Ono T, Yamanoi A, Tachibana M, Nagasue N.

J Surg Oncol. 2007 Mar 1;95(3):241-9.

PMID:
17323338
17.

Expression of hypoxia inducible factor-1alpha during liver regeneration induced by partial hepatectomy in rats.

Maeno H, Ono T, Dhar DK, Sato T, Yamanoi A, Nagasue N.

Liver Int. 2005 Oct;25(5):1002-9.

PMID:
16162160
18.
19.
20.

Expression of gap junction protein connexin32 in chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.

Nakashima Y, Ono T, Yamanoi A, El-Assal ON, Kohno H, Nagasue N.

J Gastroenterol. 2004 Aug;39(8):763-8.

PMID:
15338370
21.

Doxycycline inhibits cell proliferation and invasive potential: combination therapy with cyclooxygenase-2 inhibitor in human colorectal cancer cells.

Onoda T, Ono T, Dhar DK, Yamanoi A, Fujii T, Nagasue N.

J Lab Clin Med. 2004 Apr;143(4):207-16.

PMID:
15085079
22.

Transforming growth factor-beta1 induced hepatocyte apoptosis--a possible mechanism for growth of colorectal liver metastasis.

Hayashi H, Kohno H, Ono T, Yamanoi A, Dhar DK, Ueda S, Rahman MA, Kubota H, Nagasue N.

Acta Oncol. 2004;43(1):91-7.

PMID:
15068326
23.

Transforming growth factor-beta1 released from the spleen exerts a growth inhibitory effect on liver regeneration in rats.

Ueda S, Yamanoi A, Hishikawa Y, Dhar DK, Tachibana M, Nagasue N.

Lab Invest. 2003 Nov;83(11):1595-603.

24.

Sequential changes of connexin32 and connexin26 in ischemia-reperfusion of the liver in rats.

Nakashima Y, Kohno H, EL-Assal ON, Dhar DK, Ono T, Yamanoi A, Nagasue N.

Hepatol Res. 2003 Sep;27(1):67-75.

PMID:
12957210
25.

Serum endostatin predicts tumor vascularity in hepatocellular carcinoma.

Dhar DK, Ono T, Yamanoi A, Soda Y, Yamaguchi E, Rahman MA, Kohno H, Nagasue N.

Cancer. 2002 Nov 15;95(10):2188-95.

26.
27.

Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway.

Dhar DK, Naora H, Yamanoi A, Ono T, Kohno H, Otani H, Nagasue N.

Anticancer Res. 2002 Jan-Feb;22(1A):379-86.

PMID:
12017318
28.

Selective approaches to gastric cancer patients with liver metastases: role of liver-directed chemotherapy.

Dhar DK, Kubota H, Yamanoi A, Ono T, Yashimura H, Ohno S, Tachibana M, Kohno H, Nagasue N.

Dig Liver Dis. 2001 Oct;33(7):614. No abstract available.

PMID:
11816554
29.

Repeated hepatic dearterialization for unresectable carcinomas of the liver: report of a 10-year experience.

Kimoto T, Yamanoi A, Uchida M, Makino Y, Ono T, Kohno H, Nagasue N.

Surg Today. 2001;31(11):984-90.

PMID:
11766086
30.

Preventive effect of FK143, a 5alpha-reductase inhibitor, on chemical hepatocarcinogenesis in rats.

Maruyama S, Nagasue N, Dhar DK, Yamanoi A, El-Assal ON, Satoh K, Okita K.

Clin Cancer Res. 2001 Jul;7(7):2096-104.

31.

Sinusoidal endothelial cell proliferation and expression of angiopoietin/Tie family in regenerating rat liver.

Sato T, El-Assal ON, Ono T, Yamanoi A, Dhar DK, Nagasue N.

J Hepatol. 2001 May;34(5):690-8.

PMID:
11434615
33.

Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases.

Rahman MA, Dhar DK, Yamaguchi E, Maruyama S, Sato T, Hayashi H, Ono T, Yamanoi A, Kohno H, Nagasue N.

Clin Cancer Res. 2001 May;7(5):1325-32.

34.

The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma.

El-Assal ON, Yamanoi A, Ono T, Kohno H, Nagasue N.

Clin Cancer Res. 2001 May;7(5):1299-305.

35.

Prognostic factors and survival after hepatic resection for hepatocellular carcinoma without cirrhosis.

Nagasue N, Ono T, Yamanoi A, Kohno H, El-Assal ON, Taniura H, Uchida M.

Br J Surg. 2001 Apr;88(4):515-22.

PMID:
11298618
36.

Androgen metabolism in regenerating liver of male rats: evidence for active uptake and utilization of testosterone.

Yamaguchi M, Yu L, Nazmy El-Assal O, Satoh T, Kumar Dhar D, Yamanoi A, Nagasue N.

Hepatol Res. 2001 May 1;20(1):114-127.

PMID:
11282490
37.

The influence of perioperative blood transfusion on intrahepatic recurrence after curative resection of hepatocellular carcinoma.

Makino Y, Yamanoi A, Kimoto T, El-Assal ON, Kohno H, Nagasue N.

Am J Gastroenterol. 2000 May;95(5):1294-300.

PMID:
10811342
38.

Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis.

Nagasue N, Dhar DK, Yamanoi A, Emi Y, Udagawa J, Yamamoto A, Tachibana M, Kubota H, Kohno H, Harada T.

Hepatology. 2000 May;31(5):1107-14.

PMID:
10796886
39.

[A case of ulcerative colitis with skipped lesion in right-sided colon and rectum].

Yasuda M, Aoki R, Kimura Y, Nakamoto J, Fujisawa A, Sakashita O, Takeuchi Y, Kaji M, Fuke K, Takada J, Oguro R, Yamanoi A, Torisu R, Yamamoto Y.

Nihon Shokakibyo Gakkai Zasshi. 2000 Apr;97(4):438-42. Japanese. No abstract available.

PMID:
10793566
40.

Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines.

Rahman MA, Dhar DK, Masunaga R, Yamanoi A, Kohno H, Nagasue N.

Cancer Res. 2000 Apr 15;60(8):2085-9.

41.

Major compared with limited hepatic resection for hepatocellular carcinoma without underlying cirrhosis: a retrospective analysis.

Nagasue N, Yamanoi A, el-Assal ON, Ohmori H, Tachibana M, Kimoto T, Kohno H.

Eur J Surg. 1999 Jul;165(7):638-46.

PMID:
10452257
42.

Surgical treatment of hepatocellular carcinoma associated with spontaneous portosystemic shunts.

Hayashi T, Kohno H, Yamanoi A, Kubota H, Tachibana M, Nagasue N.

Eur J Surg. 1999 Jun;165(6):543-9.

PMID:
10433137
43.

Prognostic factors after hepatic resection for hepatocellular carcinoma associated with Child-Turcotte class B and C cirrhosis.

Nagasue N, Kohno H, Tachibana M, Yamanoi A, Ohmori H, El-Assal ON.

Ann Surg. 1999 Jan;229(1):84-90.

44.

Inferior vena caval thrombosis after traumatic liver injury.

Kimoto T, Kohno H, Uchida M, Yamanoi A, Yamamoto A, Nagasue N, Ando S, Suemitsu K, Ohtani M.

HPB Surg. 1998;11(2):111-6. Review.

45.

Modulation of endothelin and nitric oxide: a rational approach to improve canine hepatic microcirculation.

Dhar DK, Yamanoi A, Ohmori H, Nakashima Y, Yamamoto A, Osama NE, Kubota H, Kohno H, Nagasue N.

Hepatology. 1998 Sep;28(3):782-8.

PMID:
9731573
47.

Proposal of invasiveness score to predict recurrence and survival after curative hepatic resection for hepatocellular carcinoma.

el-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Yu L, Nagasue N.

Surgery. 1997 Sep;122(3):571-7.

PMID:
9308615
48.
49.

Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study.

Ono T, Nagasue N, Kohno H, Hayashi T, Uchida M, Yukaya H, Yamanoi A.

Semin Oncol. 1997 Apr;24(2 Suppl 6):S6-18-S6-25.

PMID:
9151912
50.

Resection of the caudate lobe of the liver for primary and recurrent hepatocellular carcinomas.

Nagasue N, Kohno H, Yamanoi A, Uchida M, Yamaguchi M, Tachibana M, Kubota H, Ohmori H.

J Am Coll Surg. 1997 Jan;184(1):1-8.

PMID:
8989293

Supplemental Content

Loading ...
Support Center